Herceptin® (Trastuzumab)

This version of the course is no longer available.
Need multiple seats for your university or lab? Get a quote
The page below is a sample from the LabCE course . Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about (online CE course)
Herceptin® (Trastuzumab)

Herceptin®, known generically as trastuzumab, is a product of Genentech, with corporate headquarters located in San Francisco, California. Trastuzumab is a humanized monoclonal antibody that binds to the HER2 receptor. It has been shown to improve response rates, time to progression, and survival. It was approved in 1998 by the United States (US) Food and Drug Administration (FDA) for the treatment of metastatic disease.